白文娣,李曦然,马勇,李茳

• 1:广州市南沙区疾病预防控制中心
• 2:中国科学院广州生物医药与健康研究院

摘要(Abstract)：

猴痘是由猴痘病毒（Monkeypox virus, MPXV）感染引起的人兽共患性疾病，临床表现主要为发热、皮疹和淋巴结肿大。从2022年5月上旬以来，短时间内全球多地出现大量病例，且流行病学及临床特点与以往不同，引起了各界的广泛关注。接种天花疫苗可有效预防猴痘，但仍有可能出现不同程度的副反应，而单克隆抗体疗法可有效避免这一缺陷。本文将就MPXV的病原学特点及流行现状、猴痘的痘苗免疫球蛋白（Vaccinia immune globulin,VIG）治疗、MPXV单克隆抗体的筛选、应用及优化方向等领域的研究现状进行系统梳理，以期为我国猴痘的科学防控提供理论支持。

关键词(KeyWords)： 猴痘病毒;痘苗免疫球蛋白;治疗性抗体;单克隆抗体

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 白文娣,李曦然,马勇,李茳

DOI: 10.13242/j.cnki.bingduxuebao.004343

参考文献(References)：

• [1] Jezek Z, Marennikova S S, Mutumbo M, Nakano J H,Paluku K M, Szczeniowski M. Human monkeypox:a study of 2,510 contacts of 214 patients[J]. J Infect Dis,1986, 154(4):551-555.
• [2]龚震宇，龚训良. 1970-2017年西非和中非的新发猴痘疫情概况[J].疾病监测，2018, 33(06):531-532.
• [3] Simpson K, Heymann D, Brown C S, Edmunds W J,Elsgaard J, Fine P, Hochrein H, Hoff N A, Green A,Ihekweazu C, Jones T C, Lule S, Maclennan J,McCollum A, Mühlemann B, Nightingale E, Ogoina D, Ogunleye A, Petersen B, Powell J, Quantick O,Rimoin A W, Ulaeato D, Wapling A. Human monkeypox-After 40 years, an unintended consequence of smallpox eradication[J]. Vaccine, 2020, 38(33):5077-5081.
• [4] Doshi R H, Guagliardo S A J, Doty J B, Babeaux A D, Matheny A, Burgado J, Townsend M B, Morgan C N, Satheshkumar P S, Ndakala N, Kanjingankolo T,Kitembo L, Malekani J, Kalemba L, Pukuta E, N′Kaya T, Kangoula F, Moses C, McCollum A M, Reynolds M G, Mombouli J V, Nakazawa Y, Petersen B W.Epidemiologic and Ecologic Investigations of Monkeypox, Likouala Department, Republic of the Congo, 2017[J]. Emerg Infect Dis, 2019, 25(2):281-289.
• [5]猴痘防控技术指南（2022年版）[J].中国病毒病杂志，2022, 12(04):245-254.
• [6] Magnus P v, Andersen E K, Petersen K B, BirchAndersen A J A. A POX-LIKE DISEASE IN CYNOMOLGUS MONKEYS[J]. 2009, 46:156-176.
• [7] SklenovskáN, Van Ranst M. Emergence of Monkeypox as the Most Important Orthopoxvirus Infection in Humans[J]. Front Public Health, 2018,6:241.
• [8] Schneider K A, Eichner M. Does it matter who is spreading monkeypox?[J]. Lancet Infect Dis, 2022, 22(9):1266-1267.
• [9] Emergence of monkeypox in West Africa and Central Africa, 1970–2017[J]. Wkly Epidemiol Rec, 2018, 93(11):125-132.
• [10]Marennikova S S, Seluhina E M, Mal′ceva N N,Cimiskjan K L, Macevic G R. Isolation and properties of the causal agent of a new variola-like disease(monkeypox)in man[J]. Bull World Health Organ,1972, 46(5):599-611.
• [11]Di Giulio D B, Eckburg P B. Human monkeypox:an emerging zoonosis[J]. Lancet Infect Dis, 2004, 4(1):15-25.
• [12]Vaughan A, Aarons E, Astbury J, Balasegaram S,Beadsworth M, Beck C R, Chand M, O′Connor C,Dunning J, Ghebrehewet S, Harper N, HowlettShipley R, Ihekweazu C, Jacobs M, Kaindama L,Katwa P, Khoo S, Lamb L, Mawdsley S, Morgan D,Palmer R, Phin N, Russell K, Said B, Simpson A,Vivancos R, Wade M, Walsh A, Wilburn J. Two cases of monkeypox imported to the United Kingdom,September 2018[J]. Euro Surveill, 2018, 23(38).
• [13]Adegboye O A, Eugenia Castellanos M, Alele F O,Pak A, Ezechukwu H C, Hou K, Emeto T I. TravelRelated Monkeypox Outbreaks in the Era of COVID-19Pandemic:Are We Prepared?[J]. Viruses,2022, 14(6).
• [14]Wittek R. Vaccinia immune globulin:current policies,preparedness, and product safety and efficacy[J]. Int J Infect Dis, 2006, 10(3):193-201.
• [15]Nalca A, Rimoin A W, Bavari S, Whitehouse C A.Reemergence of monkeypox:prevalence, diagnostics,and countermeasures[J]. Clin Infect Dis, 2005, 41(12):1765-1771.
• [16]Kempe C H, Berge T O, England B. Hyperimmune vaccinal gamma globulin; source, evaluation, and use in prophylaxis and therapy[J]. Pediatrics, 1956, 18(2):177-188.
• [17]Corporation C. Vaccinia Immune Globulin Intravenous(Human)(VIGIV)package insert.[EB/OL].[2005].http：//www. fda. gov/cber/label/vigivcan050305LB.pdf.
• [18]Crickard L, Babas T, Seth S, Silvera P, Koriazova L,Crotty S. Protection of rabbits and immunodeficient mice against lethal poxvirus infections by human monoclonal antibodies[J]. PLoS One, 2012, 7(11):e48706.
• [19]Greenberg R N, Kennedy J S. ACAM2000:a newly licensed cell culture-based live vaccinia smallpox vaccine[J]. Expert Opin Investig Drugs, 2008, 17(4):555-564.
• [20]Kempe C H. Studies smallpox and complications of smallpox vaccination[J]. Pediatrics, 1960, 26:176-189.
• [21]Smallpox vaccination and adverse reactions:guidance for clinicians[J]. Ann Pharmacother, 2003, 37(3):467-468.
• [22]Hopkins R J, Lane J M. Clinical efficacy of intramuscular vaccinia immune globulin:a literature review[J]. Clin Infect Dis, 2004, 39(6):819-826.
• [23]Nanning W. Prophylactic effect of antivaccinia gammaglobulin against post-vaccinal encephalitis[J]. Bull World Health Organ, 1962, 27(3):317-324.
• [24]Wharton M, Strikas R A, Harpaz R, Rotz L D,Schwartz B, Casey C G, Pearson M L, Anderson L J.Recommendations for using smallpox vaccine in a preevent vaccination program.Supplemental recommendations of the Advisory Committee on Immunization Practices(ACIP)and the Healthcare Infection Control Practices Advisory Committee(HICPAC)[J]. MMWR Recomm Rep, 2003, 52(Rr-7):1-16.
• [25]Maurer D M, Harrington B, Lane J M. Smallpox vaccine:contraindications, administration, and adverse reactions[J]. Am Fam Physician, 2003, 68(5):889-896.
• [26]Schmaljohn C, Cui Y, Kerby S, Pennock D, Spik K.Production and characterization of human monoclonal antibody Fab fragments to vaccinia virus from a phagedisplay combinatorial library[J]. Virology, 1999, 258(1):189-200.
• [27]Gu X, Zhang Y, Jiang W, Wang D, Lu J, Gu G, Qin C, Fang M. Protective Human Anti-Poxvirus Monoclonal Antibodies Are Generated from Rare Memory B Cells Isolated by Multicolor Antigen Tetramers[J]. Vaccines(Basel), 2022, 10(7).
• [28]Beer E M, Rao V B. A systematic review of the epidemiology of human monkeypox outbreaks and implications for outbreak strategy[J]. PLoS Negl Trop Dis, 2019, 13(10):e0007791.
• [29]Mucker E M, Wollen-Roberts S E, Kimmel A,Shamblin J, Sampey D, Hooper J W. Intranasal monkeypox marmoset model:Prophylactic antibody treatment provides benefit against severe monkeypox virus disease[J]. PLoS Negl Trop Dis, 2018, 12(6):e0006581.
• [30]Xu C, Meng X, Yan B, Crotty S, Deng J, Xiang Y.An epitope conserved in orthopoxvirus A13 envelope protein is the target of neutralizing and protective antibodies[J]. Virology, 2011, 418(1):67-73.
• [31]Moss B. Smallpox vaccines:targets of protective immunity[J]. Immunol Rev, 2011, 239(1):8-26.
• [32]Fogg C, Lustig S, Whitbeck J C, Eisenberg R J,Cohen G H, Moss B. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions[J]. J Virol, 2004, 78(19):10230-10237.
• [33]Lustig S, Fogg C, Whitbeck J C, Eisenberg R J,Cohen G H, Moss B. Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge[J]. J Virol, 2005, 79(21):13454-13462.
• [34]Gilchuk I, Gilchuk P, Sapparapu G, Lampley R, Singh V, Kose N, Blum D L, Hughes L J, Satheshkumar P S, Townsend M B, Kondas A V, Reed Z, Weiner Z,Olson V A, Hammarlund E, Raue H P, Slifka M K,Slaughter J C, Graham B S, Edwards K M, Eisenberg R J, Cohen G H, Joyce S, Crowe J E, Jr. CrossNeutralizing and Protective Human Antibody Specificities to Poxvirus Infections[J]. Cell, 2016, 167(3):684-694.e689.
• [35]Golden J W, Zaitseva M, Kapnick S, Fisher R W,Mikolajczyk M G, Ballantyne J, Golding H, Hooper J W. Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease[J]. Virol J, 2011, 8:441.
• [36]Haurum J S. Recombinant polyclonal antibodies:the next generation of antibody therapeutics?[J]. Drug Discov Today, 2006, 11(13-14):655-660.
• [37]Thran M, Mukherjee J, P?nisch M, Fiedler K, Thess A, Mui B L, Hope M J, Tam Y K, Horscroft N,Heidenreich R, Fotin-Mleczek M, Shoemaker C B,Schlake T. mRNA mediates passive vaccination against infectious agents, toxins, and tumors[J]. EMBO Mol Med, 2017, 9(10):1434-1447.
• [38]Tiwari P M, Vanover D, Lindsay K E, Bawage S S,Kirschman J L, Bhosle S, Lifland A W, Zurla C,Santangelo P J. Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infection[J]. Nat Commun, 2018, 9(1):3999.
• [39]Deng Y Q, Zhang N N, Zhang Y F, Zhong X, Xu S,Qiu H Y, Wang T C, Zhao H, Zhou C, Zu S L, Chen Q, Cao T S, Ye Q, Chi H, Duan X H, Lin D D,Zhang X J, Xie L Z, Gao Y W, Ying B, Qin C F. Lipid nanoparticle-encapsulated mRNA antibody provides long-term protection against SARS-CoV-2 in mice and hamsters[J]. Cell Res, 2022, 32(4):375-382.
• [40]Chen B, Chen Y, Li J, Wang C, Song W, Wen Y,Lin J, Wu Y, Ying T. A Single Dose of Anti-HBsAg Antibody-Encoding mRNA-LNPs Suppressed HBsAg Expression:a Potential Cure of Chronic Hepatitis B Virus Infection[J/OL]. mBio, 2022, 13(4):e0161222.